The 2008 Oncology on Canvas: Expressions of a Cancer Journey art competition and exhibition, sponsored by Eli Lilly and Company in partnership with the National Coalition for Cancer Survivorship, is accepting entries to be received no later than June 30, 2008.
The 2008 Oncology on Canvas: Expressions of a Cancer Journey art competition and exhibition, sponsored by Eli Lilly and Company in partnership with the National Coalition for Cancer Survivorship, is accepting entries to be received no later than June 30, 2008.
The biennial competition invites people diagnosed with any type of cancer, their families, friends, caregivers, and healthcare providers to express, through art and narrative, the life-affirming changes that give their cancer journey meaning.
Entries can be from any of six different art media: oil, watercolor, acrylic, photography, pastel, and mixed media (any other type of one-dimensional art). Submitted artwork must be at least 12″ × 12″ and no larger than 17″ × 26″.
Artists can enter via three categories: person diagnosed with cancer; healthcare professional, eg, doctor, nurse, pharmacist, lab technician; and family member, friend, or caregiver.
An independent panel of judges will select three top prize winners who will be awarded prize money to be donated directly to a cancer charity of their choice: 1st prize $10,000, 2nd prize $5,000, and 3rd prize $2,500. Additional winners will be selected from each medium and participant category with awards of $1,000.
The 2006 1st prize US winner, for example, donated her winnings to the University of North Carolina Lineberger Comprehensive Cancer Center, while the 3rd prize winnings went to the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins.
For more information or to obtain an entry form and content criteria, please call 1-800-734-4131, or log on to www.LillyOncologyOnCanvas.com.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.